Analysts’ Weekly Ratings Updates for Ligand Pharmaceuticals (LGND)

Several analysts have recently updated their ratings and price targets for Ligand Pharmaceuticals (NASDAQ: LGND):

• 9/25/2026 – Ligand Pharmaceuticals is now covered by Barclays PLC. They set an “overweight” rating and a $345.00 price target on the stock.
• 9/24/2026 – Ligand Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $358.00 price target on the stock.
• 9/23/2026 – Ligand Pharmaceuticals had its price target raised by Citigroup Inc. from $390.00 to $397.00. They now have a “buy” rating on the stock.
• 9/21/2026 – Ligand Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 8/14/2026 – Ligand Pharmaceuticals is now covered by Leerink Partners. They set an “outperform” rating and a $330.00 price target on the stock.
• 8/11/2026 – Ligand Pharmaceuticals was upgraded by Weiss Ratings from “hold (c)” to “buy (b-)”.
• 8/7/2026 – Ligand Pharmaceuticals had its price target raised by Royal Bank Of Canada from $340.00 to $345.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Ligand Pharmaceuticals had its price target raised by HC Wainwright from $289.00 to $358.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Ligand Pharmaceuticals had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $326.00 price target on the stock, up from $285.00.

Insiders Place Their Bets

In other Ligand Pharmaceuticals news, CFO Octavio Espinoza sold 31,641 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $292.06, for a total value of $9,241,070.46. Following the completion of the sale, the chief financial officer owned 27,696 shares in the company, valued at approximately $8,088,893.76. This trade represents a 53.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jason Haas sold 7,138 shares of Ligand Pharmaceuticals stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $292.81, for a total transaction of $2,090,077.78. Following the completion of the sale, the director owned 3,981 shares in the company, valued at approximately $1,165,676.61. This trade represents a 64.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 49,979 shares of company stock worth $14,548,548 in the last quarter. 5.60% of the stock is currently owned by company insiders.

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and licenses technologies and drug assets to pharmaceutical and biotechnology partners. Rather than operating primarily as a traditional commercial drug manufacturer, Ligand focuses on building a portfolio of royalty agreements, licensing arrangements and other partnerships that can generate payments when partnered products are developed, approved and sold.

The company’s best-known technology is Captisol, a chemically modified cyclodextrin designed to improve the solubility, stability and delivery of certain drug compounds.